Gary J. Kurtzman, MD, Senior Vice President, and Managing Director of the Safeguard Life Sciences Group, presented the story of Shire's acquisition of Advanced BioHealing (ABH) at the 2011 Southeast BIO Investor Forum in North Carolina. This presentation details how ABH established a viable commercial infrastructure with the help of Safeguard, leading to an acquisition by Shire.

1. The Story of Shire ’s Acquisition of Advanced BioHealing, Inc.

5. Major Milestones To be as brave as the people we help 1990’s: Advanced Tissue Sciences (ATS) invests >$300M developing Dermagraft & TransCyte 2000: ATS forms marketing partnership with Smith & Nephew 2001: DG approved by the FDA to treat DFU 2002: ATS files for bankruptcy 2003: S&N purchases DG from bankruptcy and continues with commercialization

6. Major Milestones To be as brave as the people we help 2005: Smith & Nephew shuts down production 2006: ABH purchases assets 2007: First ABH manufactured DG shipped in the U.S. 2010: DG sales reach $147M in U.S. 2011: Shire completes $750M acquisition of ABH

7. Fund Raising To be as brave as the people we help 2003 $2.4M 2005 Series A $8.0M Series B 2007 $30.0M Series C $10.0M Friends, family & angels

8. Robust Revenue Growth To be as brave as the people we help CAGR = 157% Annual Revenue (in millions) 2Q11 vs. 2Q10 (in millions) 2Q11 32%

10. Evaluation of Options To be as brave as the people we help

11. Down To The Wire To be as brave as the people we help January May 2011

17. Investor Perspective To be as brave as the people we help January May 2011 Fear and Greed Greed More Greed

18. Investor Perspective To be as brave as the people we help

26. Thank You